Quality of Recovery After Reversal With Neostigmine or Sugammadex.
Pulmonary Function, Muscle Strength, Time to Extubation and Quality of Recovery in the Post Anesthesia Care Unit After Reversal of Neuromuscular Blockade With Neostigmine or Sugammadex.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Sugammadex has been shown to have a faster onset and more reliable reversal of neuromuscular blockade when compared to neostigmine as measured by return of Train-of-four (TOF) ratio to >0.9. (Breuckmann, 2015) The investigator's hypothesis is that sugammadex will be associated with improved deep breathing as measured by incentive spirometry in the PACU. The investigators also hypothesize that patients reversed with sugammadex will have shorter times to extubation and better recovery profiles in the PACU as measured by strength, PACU discharge readiness and quality of recovery scores.
Residual neuromuscular blockade after surgery can result in airway compromise, pulmonary complications, and possible need for reintubation and can be a negative experience for patients. Reintubation after surgery is currently a quality measure in NSQIP (National Surgery Quality Improvement Program) A TOF ratio of <0.9 has been identified as a marker of residual neuromuscular blockade in the PACU. (Farhan 2013) Several clinical trials have shown that reversal of neuromuscular blockade with sugammadex results in a faster and more reliable return to TOF ratio of >0.9 when compared to neostigmine. However most of these studies primarily report on TOF ratios. There are scant data on clinical outcomes after reversal with neostigmine versus sugammadex. Incentive spirometry is a clinically meaningful measurement of postoperative pulmonary function, i.e the ability to breath deeply, which minimizes atelectasis and risk of postoperative pneumonia.
The investigators will compare recovery profiles of patients who have received sugammadex or neostigmine for reversal of neuromuscular blockade after surgery. The primary outcome will be incentive spirometry volumes after surgery as a measure of pulmonary function. The secondary measures include hand grip measured using a dynamometer, time to extubation, time to PACU discharge, time to sit independently, and quality of recovery 15 survey scores.
This will be a single-center, prospective, randomized, assessor blinded, controlled trial. Patients will be randomized to either receive sugammadex or neostigmine for the reversal of neuromuscular blockade. The anesthesiologist will be unblinded to the study drug however the assessor in the PACU will be blinded.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
New York
-
Stony Brook, New York, Stati Uniti, 11794
- Stony Brook University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant must be willing and able to provide written informed consent for the study
- Participant must be greater than or equal to 18 years of age
- Participant must be ASA (American Society of Anesthesiologists) class I, II or III
- Planned use of neuromuscular blocking drugs
- Planned use of endotracheal intubation
- Planned for extubation to occur in the OR
Exclusion Criteria:
- ASA (American Society of Anesthesiologists) Class IV
- Age < 18 years old
- Inability to give oral or written consent
- Known or suspected neuromuscular disorder impairing neuromuscular function
- True allergy to muscle relaxants
- A (family) history of malignant hyperthermia
- A contraindication for neostigmine or sugammadex administration
- Serum creatinine level of greater than 2.0 mg/dL
- Surgery where the patient's arm is not available for neuromuscular monitoring
- A plan to extubate under deep anesthesia
- Pregnant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Neostigmine
Patients in this arm will receive neostigmine for reversal of neuromuscular blockade.
Neostigmine is historically the medication that has been used for this purpose.
|
Neostigmine will be given for reversal of neuromuscular blockade.
Altri nomi:
|
|
Comparatore attivo: Sugammadex
Patients in this arm will receive sugammadex for reversal of neuromuscular blockade.
Sugammadex is a newer, FDA approved, medication for this purpose.
|
Sugammadex will be given for reversal of neuromuscular blockade.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes
Lasso di tempo: 30 Minutes
|
Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery.
The change from baseline and recovery profile will be measured.
|
30 Minutes
|
|
Incentive Spirometry, Change From Baseline and Recovery Profile - 60 Minutes
Lasso di tempo: 60 Minutes after reversal
|
Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery.
The change from baseline and recovery profile will be measured.
|
60 Minutes after reversal
|
|
Incentive Spirometry, Change From Baseline and Recovery Profile - 120 Minutes
Lasso di tempo: 120 minutes after reversal
|
Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery.
The change from baseline and recovery profile will be measured.
|
120 minutes after reversal
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Grip Strength, Change From Baseline and Recovery Profile 30 Min
Lasso di tempo: 30 minutes
|
Grip strength will be measured with a hand dynamometer
|
30 minutes
|
|
Grip Strength, Change From Baseline and Recovery Profile 60 Min
Lasso di tempo: 60 minutes after reversal
|
Grip strength will be measured with a hand dynamometer
|
60 minutes after reversal
|
|
Grip Strength, Change From Baseline and Recovery Profile 120 Min
Lasso di tempo: 120 minutes after surgery
|
Grip strength will be measured with a hand dynamometer
|
120 minutes after surgery
|
|
Time to Extubation
Lasso di tempo: Immediately after surgery, up to 30 minutes
|
Measured time between surgery end and time of extubation (removal of breathing tube)
|
Immediately after surgery, up to 30 minutes
|
|
Train of Four Ratio > 90% During PACU Admission
Lasso di tempo: At PACU admission, approximately within one hour of reversal of neuromuscular blockade reversal.
|
Train of four ratio (TOFR) is the ration of the twitch height of the 4th twitch compared to the 1st twitch during train of four neuromuscular stimulation.
This measurement was performed using a TOF Watch, which in an accelemyographer.
Electric current is applied to the ulnar nevre and the twitches are measured in the thumb.
Adequate reversal of neuromuscular blockade is defined as a TOFR >90%.
|
At PACU admission, approximately within one hour of reversal of neuromuscular blockade reversal.
|
|
Quality of Recovery 15 Survey
Lasso di tempo: Postoperative day number one
|
15 question survey to assess patient's overall quality of recovery after anesthesia/surgery. Quality of Recovery 15 Survey. Minimum: 0 Maximum: 150 Higher Scores mean a better outcome and better quality of recovery. Part A: How have you been feeling in the last 24 hours? 0 = none of the time (poor), 10 = all of the time (excellent). Examples: able to breath easily, able to enjoy food, feeling rested. etc. Part B: Have you had any of the following in the last 24 hours? 10 to 0, where 10 = none of the time (Excellent) and 0 = all of the time (poor). Examples: moderate pain, nausea or vomiting, feeling worried or anxious, etc. |
Postoperative day number one
|
|
Time to Readiness for Post Anesthesia Care Unit (PACU) Discharge (Aldrete Score >9)
Lasso di tempo: Within 4 hours from the end of surgery
|
Measured time between PACU admission and meeting PACU discharge readiness.
PACU discharge was defined as when the patient had an Aldrete score of 9 or higher as determined by the PACU nurse.
The Aldrete score is a measure of post anesthesia recovery.
0 is poor condition and 10 is excellent condition.
There are 5 assessment items (able to move voluntary, breathing, consciousness, circulation (BP) and spO2) which are graded on a 0-2 point scale with 0 being poor and 2 being excellent.
|
Within 4 hours from the end of surgery
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Ramon Abola, MD, Stony Brook Medicine, Department of Anesthesiology
Pubblicazioni e link utili
Pubblicazioni generali
- Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, Maktabi M, Lee J, Kwo J, Pino R, Sabouri AS, McGovern F, Staehr-Rye AK, Eikermann M. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015 Nov;115(5):743-51. doi: 10.1093/bja/aev104. Epub 2015 May 2.
- Farhan H, Moreno-Duarte I, McLean D, Eikermann M. Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery? Curr Anesthesiol Rep. 2014 Dec;4(4):290-302. doi: 10.1007/s40140-014-0073-6.
- Abola RE, Romeiser J, Rizwan S, Lung B, Gupta R, Bennett-Guerrero E. A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength. Can J Anaesth. 2020 Aug;67(8):959-969. doi: 10.1007/s12630-020-01695-4. Epub 2020 May 13.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 917402-3
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .